“Patient Preference for Calcipotriene 0.005%/Betamethasone Dipropionate 0.064% Foam or Topical Suspension vs. Latest Topical Treatment in the PSO-INSIGHTFUL Study” (2017) SKIN The Journal of Cutaneous Medicine, 1(3.1), p. s26. doi:10.25251/skin.1.supp.25.